Belite Bio BLTE 深 滬
等待開盤 11-11 09:30:00 美东时间
156.52
-1.170
-0.74%
華盛通- 最 高161.28
- 今 開156.40
- 成交量 17.70万股
- 最 低 153.75
- 昨 收 157.69
- 總市值 63.03亿
- 52周最高 200.00
- 市盈率 靜 --
- 換手率 0.44%
- 52周最低 115.41
- 委 比 -33.70%
- 總股本 4027.21万
- 歷史最高 200.00
- 量 比 1.00
- 振 幅 4.78%
- 歷史最低 8.80
- 每 手 1
- 風險率 15.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
Belite Bio, Inc. (NASDAQ: BLTE) will host a webcast on November 12, 2026, at 4:30 p.m. Eastern Time to discuss its third-quarter 2026 financial results and provide a business update. The webcast will be available via the provided link or the Company’s Investor Relations website, with a replay following the event. Belite Bio focuses on developing novel therapeutics for degenerative retinal diseases, with its lead candidate, tinlarebant, targeting ...
11-05 13:00
大摩一口气覆盖八家生物科技公司！PTC Therapeutics(PTCT.US)、Belite Bio(BLTE.US)获看好 点名多款潜力重磅药物
摩根士丹利在近日发布的研报中首次覆盖八家生物科技公司，业务涉及罕见病、眼科、肺部疾病以及神经精神疾病领域。
10-20 09:40
Belite Bio Files Marketing Authorization Application In Singapore, U.K., Switzerland For Tinlarebant To Treat Stargardt Disease Type 1
Belite Bio, Inc (NASDAQ: BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced Marketing Authorization Application (MAA) submissions ...
10-15 04:04
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
Belite Bio has submitted Marketing Authorization Applications (MAAs) for tinlarebant in Singapore, the UK, and Switzerland to treat Stargardt disease type 1 (STGD1). Tinlarebant, an investigational oral therapy, aims to slow retinal lesion growth in STGD1, a rare, inherited disease with no approved treatments in these regions. The MAA submissions via the Access Consortium framework support Belite’s global goal to bring tinlarebant to STGD1 patien...
10-14 20:00
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Belite Bio, a clinical-stage drug development company, announced that its data will be presented at the Euretina Innovation Spotlight (EIS) on September 30, 2026, and Euretina from October 1-4, 2026, in Vienna, Austria. The EIS presentation, titled "Belite Bio Company Overview," will be delivered by Hendrik Scholl, M.D., at 2:28 – 3:06 p.m. CEST in Room 1/Hall A. The Euretina presentation, titled "Topline Results from the Phase 3 DRAGON Study of ...
09-29 00:00
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
美股周涨跌榜 | 生物医药企业SMMT周涨逾28%！关键药物取得突破；加密货币概念股齐升，IREN周内大涨26%
生物医药企业SMMT周涨逾28%！关键药物取得突破；加密货币概念股齐升，IREN周涨26%！受比特币反弹及云业务双重催化；Strive涨近25%，四天增持约1,800枚比特币>>
09-05 10:16
美股牛股 | Belite Bio飙升13.2%，获大行看高至303美元，潜在升幅约77%；存储、光通信板块逆势狂涨！Aehr Test Systems劲升13%，闪迪升近12%
Belite Bio飙升13.2%，获大行看高至303美元，潜在升幅约77%；存储、光通信板块逆势狂涨！Aehr Test Systems劲升13%，闪迪升近12%>>
09-05 06:25
Why Is Belite Bio Stock Soaring Friday?
Belite Bio Inc. (NASDAQ:BLTE) drew a bullish initiation from Canaccord Genuity, which sees significant upside tied to the potential launch of its lead eye-disease drug, tinlarebant. Canaccord analyst Whitney Ijem initiated coverage with a Buy rating and a $303 price forecast. That compares with Beli...
09-05 01:41
